Products Liability Law Daily Wrap Up, SETTLEMENT AGREEMENTS—HOUSEHOLD PRODUCTS—Johnson & Johnson proposes $5.5 billion ovarian talc settlement, (Jul 28, 2026)

By WK Editorial Staff

The agreement “brings finality” to the 15-year litigation, the company said.

Johnson & Johnson announced that it has reached an agreement with the plaintiff firms leading the federal and state ovarian talc litigation to resolve the remaining lawsuits. The proposed settlement is conditioned on several requirements, including participation by plaintiff firms representing at least 95% of the approximately 76,000 remaining claims. Johnson & Johnson said the agreement follows a favorable ruling by the multi-district litigation (MDL) court (Johnson & Johnson Press Release (July 27, 2026)).

MDL court ruling. According to the company, the MDL court on July 22, 2026, ordered the plaintiffs to show why the remaining talc claims should not be dismissed for failure to establish specific causation. Johnson & Johnson said the order came after the plaintiffs withdrew specific-causation experts in two bellwether cases following a hearing that examined the reliability of those experts’ methodologies. The company stated that the ruling supported its longstanding position that the claims could not establish a causal connection between its talc products and individual cases of ovarian cancer.

Settlement terms. In announcing the proposed resolution, Johnson & Johnson said it is committing $5.5 billion for claim payments. The first payment, not to exceed $3 billion, would be made in 2027, with no additional payments due before 2028. The agreement also requires participation by lead plaintiff firms in ovarian talc litigation pending in state and federal courts and is contingent upon reaching the required participation threshold.

Prior litigation. The company said the proposed agreement builds on previous efforts to resolve talc-related litigation. Johnson & Johnson stated that it has already settled about 95% of filed mesothelioma lawsuits, resolved state consumer protection claims, and settled disputes with talc suppliers. Company officials said the agreement would provide a path toward concluding the remaining ovarian talc litigation.

Company statements. Johnson & Johnson reiterated its position that studies and scientific research support the safety of cosmetic talc and that talc does not cause cancer. The company also noted that it discontinued talc-based JOHNSON’S® Baby Powder globally in 2023 as a commercial decision and separated its consumer health business, Kenvue, later that year. Johnson & Johnson said it retained responsibility for talc-related liabilities and agreed to indemnify Kenvue for litigation costs arising from talc-related lawsuits in the United States and Canada.

MainStory: TopStory SettlementAgreementsNews HouseholdProductsNews AsbestosNews ClassActLitigationNews NewJerseyNews GCNNews